Deal craters for USADA to oversee horse racing anti-doping

Sports

Sport Highlights

COLORADO SPRINGS, Colo. (AP) — A deal for the U.S. Anti-Doping Agency to police drugs in horse racing cratered Thursday after months of negotiations that the agency’s CEO said did not give it “a reasonable chance to put in place a credible and effective program.”

USADA was set to become the regulator for anti-doping and medication control for thoroughbred racing under the Horseracing Integrity and Safety Act, which is set to go into effect next July.

But in a surprising announcement, CEO Travis Tygart said the deal stalled.

“While we desperately tried to reach an agreement to implement the program, without compromising our values, we have always said the passing of the legislation and the finalization of uniform, robust rules are huge victories for the horses and the equine industry,” Tygart said.

He did not offer specifics about the disagreements that scuttled the deal.

The lack of uniform rules across the nation came into focus after Medina Spirit tested positive for a banned substance after the Kentucky Derby. One key issue was the length of time it would take to corroborate the test with a “B” sample, which was needed to confirm the positive.

USADA said part of its program would have ensured a faster turnaround on the “B” sample.

Medina Spirit ended up racing, and finishing third, in the Preakness, the second leg of the Triple Crown, even though his victory in the Kentucky Derby was in dispute.

Earlier this month, Medina Spirit collapsed and died after a workout at Santa Anita.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Local Sports

More Local Sports

Download our news app

App Store Link
Google Play Link

Check the latest closings and delays

MEET THE NEWS10 SPORTS TEAM

Liana Bonavita

Griffin Haas

GRIFFIN HAAS

Jared Phillips

Latest PODCAST episode

More PODCAST: On the Story with Trishna Begam
CHECK OUT OUR NEW APP FEATURES

Latest COVID-19 News

More COVID-19